14703-92-5

Basic information

• Product Name: 2-(4-Bromophenylthio)ethanol
• Synonyms: 2-(4-Bromophenylthio)ethanol;2-(p-Bromophenylthio)ethanol
• CAS NO: 14703-92-5
• Molecular Formula: C₈H₉BrOS
• Molecular Weight: 233.13
• Mol File: 14703-92-5.mol

Chemical Properties

• Boiling Point: 322.8°C at 760 mmHg
• Flash Point: 149°C
• Appearance: /
• Density: 1.57g/cm³
• Vapor Pressure: 0.000112mmHg at 25°C
• Refractive Index: 1.641
• CAS DataBase Reference: 2-(4-Bromophenylthio)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Bromophenylthio)ethanol(14703-92-5)
• EPA Substance Registry System: 2-(4-Bromophenylthio)ethanol(14703-92-5)

Safety Data

• Hazardous Substances Data: 14703-92-5(Hazardous Substances Data)

Usage

General Description

2-(4-Bromophenylthio)ethanol, also known as 4-Bromophenethyl thioether, is an organic compound with the chemical formula C8H9BrOS. It is a colorless to faintly yellow liquid with a molecular weight of 233.12 g/mol. 2-(4-Bromophenylthio)ethanol is used in the synthesis of pharmaceuticals and as a building block in organic chemistry. It is also utilized as a reagent in chemical reactions and as a fragrance ingredient in perfumes and cosmetics. 2-(4-Bromophenylthio)ethanol is considered to be a potentially hazardous chemical and should be handled with care, and appropriate safety measures should be taken when working with it.

InChI:InChI=1/C8H9BrOS/c9-7-1-3-8(4-2-7)11-6-5-10/h1-4,10H,5-6H2

Upstream product

• 139139-81-4 bis(4-bromophenyl)iodonium triflate 
• 107-21-1 ethylene glycol 
• 65251-10-7 ethyl 2-((4-bromophenyl)thio)acetate 
• 106-37-6 1.4-dibromobenzene 
• 60-24-2 2-hydroxyethanethiol 
• 106-53-6 para-bromobenzenethiol 
• 107-07-3 2-chloro-ethanol 
• 100-39-0 benzyl bromide 
• 540-51-2 2-bromoethanol 

Downstream Products

• 107737-89-3 4-(2-hydroxyethylsulfonyl)bromobenzene 
• 90561-24-3 <4-Bromphenyl>-<2-methylsulfonyloxy-aethyl>-sulfon 
• 122865-60-5 N-<2-(4-bromophenylsulphonyl)ethoxycarbonyl>-L-trytophan dimethylamide 
• 122885-16-9 2-(4-bromophenylsulphonyl)ethyl succinimido carbonate 
• 122865-52-5 2-(4-bromophenylsulphonyl)ethyl chloroformate 
• 485799-95-9 2-[2-(3'-cyanomethyl-biphenyl-4-sulfonyl)-ethoxy]-naphthalene-1-carboxylic acid benzyl ester 
• 485799-93-7 2-[2-(3'-cyanomethyl-biphenyl-4-ylsulfanyl)-ethoxy]-naphthalene-1-carboxylic acid benzyl ester 
• 279245-96-4 2-[2-(4'-chlorobiphenyl-4-sulfonyl)ethoxy]naphthalene-1-carboxylic acid benzyl ester 
• 485799-94-8 2-[2-(4'-methoxy-biphenyl-4-sulfonyl)-ethoxy]-naphthalene-1-carboxylic acid benzyl ester 

Relevant articles and documents

DIPHENYL DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

INDOLE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeleta

NEW COMPOUND

PROBLEM TO BE SOLVED: To provide a new compound that does not have structural similarity to ceramide and has excellent CERT inhibitory activity. SOLUTION: The present invention provides a new compound of structural formula (I). A bond group -X- is cis-cyclopropyl-, R1, R2, R3, R4, and R5 independently represent a hydrogen atom, a halogen atom, a linear or branched C1-C8 alkyl group that may have a halogen atom, or OR6. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2020,JPOandINPIT

INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR)

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to substituted indole compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, adisease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

Identification of biaryl sulfone derivatives as antagonists of the histamine H3 receptor: Discovery of (R)-1-(2-(4′-(3- methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916)

The design of a new clinical candidate histamine-H3 receptor antagonist for the potential treatment of excessive daytime sleepiness (EDS) is described. Phenethyl-R-2-methylpyrrolidine containing biphenylsulfonamide compounds were modified by re

Design, Synthesis, and Evaluation of 2-(arylsulfonyl)oxiranes as Cell-permeable Covalent Inhibitors of Protein Tyrosine Phosphatases

A structure-based design approach has been applied to develop 2-(arylsulfonyl)oxiranes as potential covalent inhibitors of protein tyrosine phosphatases. A detailed kinetic analysis of inactivation by these covalent inhibitors reveals that this class of compounds inhibits a panel of protein tyrosine phosphatases in a time- and dose-dependent manner, consistent with the covalent modification of the enzyme active site. An inactivation experiment in the presence of sodium arsenate, a known competitive inhibitor of protein tyrosine phosphatase, indicated that these inhibitors were active site bound. This finding is consistent with the mass spectrometric analysis of the covalently modified protein tyrosine phosphatase enzyme. Additional experiments indicated that these compounds remained inert toward other classes of arylphosphate-hydrolyzing enzymes, and alkaline and acid phosphatases. Cell-based experiments with human A549 lung cancer cell lines indicated that 2-(phenylsulfonyl)oxirane (1) caused an increase in intracellular pTyr levels in a dose-dependent manner thereby suggesting its cell-permeable nature. Taken together, the newly identified 2-(arylsulfonyl)oxiranyl moiety could serve as a novel chemotype for the development of activity-based probes and therapeutic agents against protein tyrosine phosphatase superfamily of enzymes.

One-pot catalyst-free synthesis of β-and γ-hydroxy sulfides using diaryliodonium salts and microwave irradiation

A simple and rapid one-pot protocol is described for the preparation of α- and β-hydroxy sulfides. The direct solvent-free microwave irradiation of diaryliodonium salts, potassium thiocyanate, and ethylene glycol/β-propylene glycol without any catalyst or base affords the final compounds in good yields (65-95 %) in around 10-25 min. Copyright

A new approach to the synthesis of 4-hydroxyethylsulfonylstyrene

A new, more environmentally benign route to hydroxyethylsulfonylstyrene has been developed, starting from 4-bromobenzenethiol, involving a solventless thioether formation, water-based perborate oxidation, and Suzuki-Miyaura cross coupling with a vinylborate reagent.

Facile preparation of aryl sulfides catalyzed by PEG400 and nickel without solvent

A variety of aryl sulfides were synthesized by aryl bromides with thiols, with PEG400 and nickel as catalysts under basic conditions in the absence of solvents. This article reported an easy and convenient method for formation of aryl-sulfur bonds. Copyright Taylor & Francis Group, LLC.